

# ASH 2024

## 66th ASH Annual Meeting and Exposition

December 7–10, 2024  
San Diego, US



## TOP ABSTRACTS

To help navigate the exciting content being presented at the 66th American Society of Hematology (ASH) Meeting and Exposition, December 7–10, 2024, San Diego, US, the ALL Hub Steering Committee have provided their recommendations for the top abstracts to look out for in ALL.

# ASH 2024: Top abstracts in ALL

December 7-10, 2024

**Saturday, December 7, 2024**

Abstract	Title	Speaker	Time (PT)
<b>307</b> <a href="#">View</a>	Efficacy and Toxicity of Fixed Dose Versus Reduced/PK-Adjusted Dose Pegaspargase in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of DFCI ALL Consortium Protocol 16-001	Melissa A. Burns	16:00
<b>308</b> <a href="#">View</a>	Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial	Daniel J. DeAngelo	16:15
<b>309</b> <a href="#">View</a>	A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009	Martin Schrappe	16:30
<b>310</b> <a href="#">View</a>	Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes	Erica Brivio	16:45
<b>311</b> <a href="#">View</a>	Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001	Lynda M. Vrooman	17:00
<b>312</b> <a href="#">View</a>	Efficacy and Safety of Adding Blinatumomab to First-Line Treatment for Chinese Children with B-Cell Acute Lymphoblastic Leukemia	Peijing Qi	17:15
<b>313</b> <a href="#">View</a>	Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma	Haley Newman	16:00
<b>1434</b> <a href="#">View</a>	Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the GRAALL-2014 Trial	Marie Balsat	17:30 (poster session)

## Sunday, December 8, 2024

Abstract	Title	Speaker	Time (PT)
<b>1</b> <a href="#">View</a>	Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children's Oncology Group Study AALL1731	Rachel E. Rau	14:00
<b>634</b> <a href="#">View</a>	TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL	Andrew Hughes	17:15
<b>636</b> <a href="#">View</a>	CD127-Directed Immunotherapy with Lusvertikimab Outperforms Imatinib in Preclinical ABL-Class-Fusion-Positive BCP-ALL	Lennart Lenk	17:45
<b>1420</b> <a href="#">View</a>	Liver Steatosis and Metabolic Toxicities in Acute Lymphoblastic Leukemia Adults Undergoing Asparaginase-Based Therapy: Findings from a Non-Invasive Assessment Study	Fausto A Rios-Olais	17:30 (poster session)
<b>1421</b> <a href="#">View</a>	Meta-Analysis of Complete Remission Rates Following First-Line Salvage Treatment after Anti-CD19 CAR-T Failure in Adult Patients with Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia	Jaromir Tomasik	17:30 (poster session)
<b>1422</b> <a href="#">View</a>	Safety and Efficacy Results of Dose-Adjusted Inotuzumab Ozogamicin in Adults with B Cell Acute Lymphoblastic Leukemia: A Retrospective Single-Center Experience	Erlie Jiang	17:30 (poster session)

## Monday, December 9, 2024

Abstract	Title	Speaker	Time (PT)
<b>727</b> <a href="#">View</a>	Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular Features	Walid Macaron	10:30
<b>728</b> <a href="#">View</a>	Older Age and TP53 Mutations Are Predictors for the Development of Therapy-Related Myeloid Neoplasms in Adults Undergoing Frontline Therapy for Acute Lymphoblastic Leukemia	Roberta Santos Azevedo	10:45
<b>729</b> <a href="#">View</a>	TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)	Ibrahim Aldoss	11:00
<b>730</b> <a href="#">View</a>	Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy	Martin Schrappe	11:15

Abstract	Title	Speaker	Time (PT)
<b>732</b> <a href="#">View</a>	Dose Optimization of Inotuzumab Ozogamicin in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia	Daniel J. DeAngelo	11:45
<b>835</b> <a href="#">View</a>	Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820	Sabina Chiaretti	14:45
<b>836</b> <a href="#">View</a>	Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial	Shanshan Suo	15:00
<b>837</b> <a href="#">View</a>	Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse	Nicholas J. Short	15:15
<b>838</b> <a href="#">View</a>	Immunomodulatory Effect of Dasatinib Plus Blinatumomab Versus Ponatinib Plus Blinatumomab in Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia Patients	Michela Ansunelli	15:30
<b>839</b> <a href="#">View</a>	Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial	Jieping Lin	15:45
<b>840</b> <a href="#">View</a>	Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation	Heike Pfeifer	16:00
<b>961</b> <a href="#">View</a>	Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013	Nicola Goekbuget	16:30
<b>962</b> <a href="#">View</a>	Prognostic Impact of the Genetic Risk at Baseline Associated to the MRD Clearance in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Preliminary Results of Pethema LAL19 Trial	Anna Torrent	16:45
<b>963</b> <a href="#">View</a>	Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes	Elias Jabbour	17:00
<b>965</b> <a href="#">View</a>	Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT	Susana Rives	17:30
<b>966</b> <a href="#">View</a>	CD19-CAR T Cells as Definitive Consolidation for Older Adults with B-Cell Acute Lymphoblastic Leukemia in First Complete Remission: A Pilot Study	Ibrahim Aldoss	17:45



**#ASH24**

Follow us on X to keep up to date  
with the latest from the congress

**@ALL\_Hub\_**



Brought to you by

